馬斯克澄清出售1萬部人型機械人Optimus爲虛假報道
美國藥與農業基建公司PharmAGRI聲稱計劃部署多達1萬部特斯拉(TSLA.US)Optimus Gen 3+ 機械人,特斯拉行政總裁馬斯克在社交平臺X作澄清爲虛假消息。
PharmAGRI早前表示已與特斯拉簽署意向書,準備在旗下SuperPharm與CEA設施導入大批人形機械人,用於自動化勞動及藥物管控。該公司主席兼行政總裁Stockwell更強調,憑藉Tesla機械人及獲得美國緝毒局(DEA)許可的基建,公司能更精準地擴張並符合法規要求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.